Off-label drug promotion

被引：0

|

作者：

不详

机构：

来源：

ONCOLOGY-NEW YORK | 1999年 / 13卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：1616 / 1616

页数：1

相关论文

共 50 条

[1] Off-Label Drug Use and Promotion
Gianutsos, Gerald
[J]. US PHARMACIST, 2014, 39 (10) : 55 - 64
[2] Off-Label Drug Promotion and the Use of Disclaimers
McKenney, Dina
[J]. TEXAS LAW REVIEW, 2013, 92 (01) : 231 - 252
[3] Off-label promotion
Kuehn, BM
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (06): : 673 - 673
[4] FDA off-track on off-label drug promotion
不详
[J]. LANCET, 2007, 370 (9604): : 1976 - 1976
[5] Prohibition against off-label drug promotion challenged
Woodward, Cal
[J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2012, 184 (05) : 518 - 518
[6] Manufacturers' promotion of off-label drug use: implications for drug safety
Zieve, Allison
Carome, Michael A.
[J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (09) : 1149 - 1151
[7] FDA Regulation of Off-label Drug Promotion Under Attack
Kesselheim, Aaron S.
Mello, Michelle M.
Avorn, Jerry
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (05): : 445 - 446
[8] DRUG MARKETING Off-label marketing: free speech or illegal promotion?
Silverman, Ed
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
[9] Off-label drug promotion and the ephemeral line between marketing and education
Krause, Joan H.
[J]. JOURNAL OF LAW AND THE BIOSCIENCES, 2015, 2 (03): : 705 - 711
[10] FDA is criticised for poor oversight of drug companies' promotion of off-label drug use
Tanne, Janice Hopkins
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7665):

← 1 2 3 4 5 →